论文部分内容阅读
目的评价泰脂安治疗糖尿病并发高血脂患者的疗效和安全性。方法对60例2型糖尿病并高血脂患者,在常规口服降糖药[诺和龙和(或)二甲双胍肠溶片]或应用胰岛素治疗的同时,口服泰脂安胶囊0.9g,tid,疗程12周,观察治疗前后血脂的变化和不良反应。结果经泰脂安治疗后,apoB、TC、TG及LDLC的降低值分别为(0.2±0.1)g/L、(1.4±0.8)mmol/L、(1.1±0.6)mmol/L及(0.6±0.4)mmol/L,HDLC升高值为(0.1±0.1)mmol/L,与治疗前比较均P<0.01;而糖基化血红蛋白治疗前后无明显变化。仅3%的患者有轻度的胃肠道反应。结论泰脂安对糖尿病并发高血脂患者的血脂异常有明显的调节作用,且安全性好。
Objective To evaluate the efficacy and safety of tiaizhenan in the treatment of diabetic patients with hyperlipidemia. Methods Sixty patients with type 2 diabetes mellitus and hyperlipidemia were treated with conventional oral hypoglycemic agents (Novozymes and metformin enteric-coated tablets) or insulin treatment. Week, observed before and after treatment of blood lipid changes and adverse reactions. Results The reduction of apoB, TC, TG and LDLC was (0.2 ± 0.1) g / L, (1.4 ± 0.8) mmol / L, (1.1 ± 0.6) mmol / L and 0.4 mmol / L, HDLC elevated value was (0.1 ± 0.1) mmol / L, P <0.01 compared with those before treatment, while glycosylated hemoglobin did not change significantly before and after treatment. Only 3% of patients have mild gastrointestinal reactions. Conclusion Taizhi’an has significant regulative effect on the dyslipidemia in patients with diabetes and hyperlipidemia, and has good safety.